Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Alimta or Taxotere · 1 trial · 1 indication
Overall survival (OS) was determined from the date of randomization to the date of death irrespective of the cause of death.
OS was determined from the date of randomization to the date of death irrespective of the cause of death. Kaplan-Meier estimates were used for analysis.
OS was determined from the date of randomization to the date of death irrespective of the cause of death. Kaplan-Meier estimates were used for analysis.
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Alimta or Taxotere | DRUG | 500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere) |
| erlotinib [Tarceva] | DRUG | 150mg po daily |
Inclusion Criteria: * adult patients \>=18 years of age; * histologically documented, locally advanced or recurrent or metastatic NSCLC; * measurable disease; * disease progression during 1-4 cycles of platinum-based chemotherapy. Exclusion Criteria: * any other malignancies within the last 5 yea...
Top 20 of 90 competitors
Alimta or Taxotere is used for the treatment of non-small cell lung cancer (NSCLC). It is an investigational small molecule being studied in the oncology therapeutic area. The drug is currently in Phase 3 clinical development for this indication.
Alimta or Taxotere is being developed by Roche Holding AG, a biopharmaceutical company. Roche's stock is traded under the ticker symbol RHHBY. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with non-small cell lung cancer.
Alimta or Taxotere is in Phase 3 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 3 trial for this drug has been completed, and it is no longer actively recruiting patients.
Alimta or Taxotere was studied in a Phase 3 clinical trial with the identifier NCT00556322. This completed trial enrolled 424 patients with advanced, recurrent, or metastatic non-small cell lung cancer. The study was conducted across multiple countries, including Australia, Canada, China, France, Germany, and the United Kingdom.
Alimta or Taxotere is not the same as Tarceva. The clinical trial NCT00556322 studied a combination of Tarceva (erlotinib) and standard of care chemotherapy, which included Alimta or Taxotere. These are distinct drugs with different mechanisms of action, and they were evaluated together in the trial.